Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Wistar Institute researchers identify the role of a Parkinson’s disease-related protein in cancer and T-cell activation

The Wistar Institute’s president and CEO, Dario C. Altieri, and his team have demonstrated the role of Parkin—a protein implicated in Parkinson’s disease—in the body’s innate immune response to cancer. Parkin is not expressed in several cancers. Altieri and his team engineered cancer cells to re-express Parkin and found that Parkin contributes to the production of interferons, which activate and attract T cells to fight the tumor. The lab’s findings were published in The Journal of Clinical Investigation.

September 20, 2024

Vol.50 No.35

Tumors are able to form with no DNA mutations, fly study shows

Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous injection.

September 13, 2024

Vol.50 No.34

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Wistar Institute researchers identify the role of a Parkinson’s disease-related protein in cancer and T-cell activation

Tumors are able to form with no DNA mutations, fly study shows

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

Renew today!

Subscriber content

Login

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Wistar Institute researchers identify the role of a Parkinson’s disease-related protein in cancer and T-cell activation

Tumors are able to form with no DNA mutations, fly study shows

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications